Navitoclax-piperazine

CAS No. 2143096-93-7

Navitoclax-piperazine( ABT-263-piperazine )

Catalog No. M23975 CAS No. 2143096-93-7

Navitoclax-piperazine is an inhibitor of B-cell lymphoma extra large (BCL-XL).

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
1 mL x 10 mM in DMSO 283 In Stock
5MG 158 In Stock
10MG 273 In Stock
25MG 430 In Stock
50MG 551 In Stock
100MG 775 In Stock
200MG 1042 In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Navitoclax-piperazine
  • Note
    Research use only, not for human use.
  • Brief Description
    Navitoclax-piperazine is an inhibitor of B-cell lymphoma extra large (BCL-XL).
  • Description
    Navitoclax-piperazine is an inhibitor of B-cell lymphoma extra large (BCL-XL).
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ABT-263-piperazine
  • Pathway
    Angiogenesis
  • Target
    Bcl-2
  • Recptor
    Bcl-xL
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    2143096-93-7
  • Formula Weight
    973.63
  • Molecular Formula
    C47H56ClF3N6O5S3
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO:250 mg/mL?(256.77 mM;?Need ultrasonic)
  • SMILES
    CC1(CCC(=C(C1)CN2CCN(CC2)C3=CC=C(C=C3)C(=O)NS(=O)(=O)C4=CC(=C(C=C4)N[C@H](CCN5CCNCC5)CSC6=CC=CC=C6)S(=O)(=O)C(F)(F)F)C7=CC=C(C=C7)Cl)C
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Sajid Khan, et al. A selective BCL-XL PROTAC degrader achieves safe and potent antitumor activity. Nat Med 25, 1938–1947 (2019).
molnova catalog
related products
  • FX1

    A potent, specific BCL6 BTB domain inhibitor with Kd of 7 uM, binds with a greater affinity than the natural BCL6 ligand SMRT (Kd=30 uM).

  • BAI1

    BAI1 (Bax channel blocker) is a potent inhibitor of Bax-mediated mitochondrial cytochrome C release (IC50: 0.52 μM).

  • BXI-72

    BXI-72 (NSC334072, Hoechst 33342) is a potent, selective small molecule Bcl-XL inhibitor that targets the BH3 domain of Bcl-XL (Kd=0.9 nM).